The FDA has granted approval for dupilumab for the treatment of eosinophilic esophagitis for adult and pediatric patients aged 12 years and older, according to a press release.
Dupilumab (Dupixent, Sanofi; Regeneron Pharmaceuticals, Inc.) is the first drug in the U.S. specifically indicated for the treatment of this condition.
Data also show significant improvements in quality of life and respiratory symptoms in patients with evidence of type 2 inflammation who were treated with dupilumab.
Lebrikizumab shows good long-term efficacy and reasonable safety in patients with moderate to severe atopic dermatitis according to the 52-week results from the phase 3 ADvocate1 and ADvocate2 trials.